FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC By Ogkologos - June 24, 2026 225 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TROPION-Breast02 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR A Systematic Analysis of the Global Burden of Disease from 2010... April 20, 2022 Loss of Y Chromosome in Men Makes Bladder Cancer More Aggressive July 27, 2023 Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α April 1, 2021 Mom Warns Others After Little Girl’s Skin Blisters From ‘Margarita Burn’ July 31, 2019 Load more HOT NEWS FDA Approves Durvalumab for Limited-Stage Small Cell Lung Cancer Navigating the Challenges of Gynecologic Cancer Survivorship: An Expert Perspective Frederick National Laboratory for Cancer Research: A Unique Resource for the... Atezolizumab Approved for Some Patients with Triple-Negative Breast Cancer
